Neuronal Activity Controls the Antagonistic Balance Between Peroxisome Proliferator-Activated Receptor- γ Coactivator-1 α and Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptors in Regulating Antioxidant Defenses

Francesc X. Soriano, Frédéric Lévillé, Sofia Papadia, Karen F.S. Bell,
Clare Puddifoot, and Giles E. Hardingham

Abstract

Transcriptional coactivators and corepressors often have multiple targets and can have opposing actions on transcription and downstream physiological events. The coactivator peroxisome proliferator-activated receptor- γ coactivator (PGC)-1 α is under-expressed in Huntington's disease and is a regulator of antioxidant defenses and mitochondrial biogenesis. We show that in primary cortical neurons, expression of PGC-1 α strongly promotes resistance to excitotoxic and oxidative stress in a cell autonomous manner, whereas knockdown increases sensitivity. In contrast, the transcriptional corepressor silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) specifically antagonizes PGC-1 α -mediated antioxidant effects. The antagonistic balance between PGC-1 α and SMRT is upset in favor of PGC-1 α by synaptic activity. Synaptic activity triggers nuclear export of SMRT reliant on multiple regions of the protein. Concomitantly, synaptic activity post-translationally enhances the transactivating potential of PGC-1 α in a p38-dependent manner, as well as upregulating cyclic-AMP response element binding protein-dependent PGC-1 α transcription. Activity-dependent targeting of PGC-1 α results in enhanced gene expression mediated by the thyroid hormone receptor, a prototypical transcription factor coactivated by PGC-1 α and repressed by SMRT. As a consequence of these events, SMRT is unable to antagonize PGC-1 α -mediated resistance to oxidative stress in synaptically active neurons. Thus, PGC-1 α and SMRT are antagonistic regulators of neuronal vulnerability to oxidative stress. Further, this coactivator-corepressor antagonism is regulated by the activity status of the cell, with implications for neuronal viability. *Antioxid. Redox Signal.* 14, 1425–1436.

Introduction

CHANGES IN GENE TRANSCRIPTION in response to external signals mediate the coordinated control of many adaptive biological processes. These changes are mediated by DNA sequence-specific transcription factors that bind to gene promoters and regulate their transcription. In neurons, the regulation of gene transcription by synaptic activity is an integral part of processes that regulate neuronal differentiation, development, long-term plasticity, and defenses against excitotoxic, apoptotic and oxidative insults (10, 12, 21, 24, 32). This control is classically viewed to be exerted *via* the direct modification of Ca²⁺-responsive transcription factors that bind Ca²⁺-responsive promoter elements (48). However, more recently it has become apparent that Ca²⁺ signals can

influence transcription by targeting a different class of proteins: transcriptional coactivators and corepressors (4, 15, 28, 42).

Transcription factors do not exist in isolation: most signal-dependent transcription factors require association with broad-specificity coactivators to promote transcription through the recruitment of chromatin remodeling complexes. The transcriptional coactivator peroxisome proliferator-activated receptor- γ (PPAR γ) coactivator 1 α (PGC-1 α) controls important physiological and metabolic processes in a diverse array of tissues. These include glucose metabolism, energy homeostasis, adaptive thermogenesis, and mitochondrial biogenesis (11, 37). In neurons, PGC-1 α regulates mitochondrial density, antioxidant defenses, and vulnerability to excitotoxic insults (45, 47). Moreover, it is under-expressed in

Huntington's disease (HD) as a direct result of mutant Huntingtin (mtHtt)-mediated repression, potentially contributing to HD pathogenesis (6, 27, 49). PGC-1 α mediates its effects through the coactivation of a number of transcription factors, such as nuclear respiratory factors 1 and 2, the myocyte enhancer factor 2 (MEF2) family, and nuclear receptors, including PPAR γ , estrogen receptors (ER), thyroid hormone receptor (TR), and the retinoic acid receptor (RAR) (37, 38). This coactivation involves the recruitment of chromatin-modifying complexes to the promoter, which may contain histone acetyl transferases, methyltransferases, and nucleosome destabilizing enzymes (23).

As well as associating with coactivators when in an active state, many signal-regulated transcription factors when in their basal, uninduced state are not merely inactive but mediate active repression *via* the association of broad-specificity corepressors. As such, transcription factor activity can be influenced by the balance between coactivator and corepressor activity. A key corepressor is silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) that interacts with many signal-dependent transcription factors (19) and mediates repression by recruiting further repressors such as class I and II histone deacetylases (HDACs) (18, 19). SMRT represses many transcription factors that are coactivated by PGC-1 α , including PPAR γ , ER, TR, RAR, and MEF2s (19, 35, 46, 50). This raises the possibility that SMRT may antagonize some of the physiological processes mediated by PGC-1 α .

Here we have studied how PGC-1 α and SMRT control cortical neuronal vulnerability to oxidative and excitotoxic insults, and the influence of neuronal activity on these transcriptional coregulators. We find that SMRT can block the ability of PGC-1 α to protect neurons against oxidative insults, but cannot antagonize the antiexcitotoxic effect of PGC-1 α expression. Further, we find that neuronal activity, by activating PGC-1 α and repressing SMRT function, upsets this antagonistic balance in favor of the neuroprotective PGC-1 α .

Materials and Methods

Neuronal cultures and stimulations

Cortical neurons from E21 Sprague Dawley rats were cultured as described (2) except that the growth medium was comprised of Neurobasal A medium + B27 (Invitrogen), 1% rat serum, and 1 mM glutamine. Experiments were performed after a culturing period of 9–10 days during which cortical neurons develop a rich network of processes, express functional *N*-methyl *D*-aspartate (NMDA)-type and AMPA/kainate-type glutamate receptors, and form synaptic contacts. Stimulations were performed after transferring neurons into a defined medium lacking trophic support "TMO" (33): 10% MEM (Invitrogen), 90% Salt-Glucose-Glycine medium (1); Salt-Glucose-Glycine: 114 mM NaCl, 0.219% NaHCO₃, 5.292 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, 1 mM Glycine, 30 mM Glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolarity 325 mosm/l, hereafter TMO. Stimulations were initiated approximately 48 h after transfection. Bursts of action potential firing were induced by treatment of neurons with 50 μ M bicuculline (BiC), and burst frequency was enhanced by addition of 250 μ M 4-amino pyridine (14). 3,3',5-Triiodo-L-thyronine (T3 hormone) was used at 50 nM. The p38 inhibitor SB203580 (Calbiochem) at 5 mM was added 30 min before the stimulation.

Western blotting and antibodies

Total cell lysates were boiled at 100°C for 5 min in 1.5 $\times$ sample buffer (1.5 M Tris pH 6.8; Glycerol 15%; SDS 3%; β -mercaptoethanol 7.5%; bromophenol blue 0.0375%). Gel electrophoresis and Western blotting were performed using Xcell Surelock system (Invitrogen) using precast gradient gels (4%–20%) according to the manufacturer's instructions. The gels were blotted onto PVDF membranes, which were then blocked for 1 h at room temperature with 5% (w/v) nonfat dried milk in TBS with 0.1% Tween 20. The membranes were then incubated at 4°C overnight with the primary antibodies diluted in blocking solution: anti-PGC-1 α (1:1000; a gift from Marc Montminy, The Salk Institute), enhanced green fluorescent protein (eGFP; 1:1000; Invitrogen), and Akt (1:500; Cell Signalling). For observation of Western blots, HRP-based secondary antibodies were used followed by chemiluminescent detection on Kodak X-Omat film.

RNA isolation, reverse transcriptase-polymerase chain reaction, and quantitative polymerase chain reaction

RNA was isolated using the Qiagen RNeasy isolation reagents (including the optional DNase treatment) following passage of the cells through a QiaShredder column. For quantitative polymerase chain reaction (qPCR), cDNA was synthesized from 1 to 3 μ g RNA using the Stratascript qPCR cDNA Synthesis kit (Stratagene, Amsterdam, Netherlands) according to the manufacturer's instructions. Briefly, the required amount of RNA (up to 3 μ g) was diluted in RNase-free water (up to 7 μ L final volume) and mixed on ice with 1 $\times$ cDNA Synthesis master mix (10 μ L), random primers: oligo-dT primers 3:1 (total 2 μ L–200 ng) and either 1 μ L RT/RNase block enzyme mixture (for RT reactions) or 1 μ L water (for No RT control reactions). Reaction mixtures were mixed and spun down and incubated for 2 min at 25°C, 40 min at 42°C, and 5 min at 95°C. cDNA was stored at –20°C. Dilutions of this cDNA were subsequently used for real-time PCR (cDNA equivalent to 6 ng of initial RNA per 15 μ L qPCR reaction except GAPDH; cDNA equivalent to 2 ng initial RNA per 15 μ L reaction for GAPDH). qPCR was performed in an Mx3000P QPCR System (Stratagene) using Brilliant SYBR Green QPCR Master Mix (Stratagene) according to the manufacturer's instructions. Briefly, the required amount of template was mixed on ice with 1 $\times$ Brilliant SYBR Green Master Mix, the required concentration of forward and reverse primers, 30 nM ROX passive reference dye, and water to the required reaction volume. Technical replicates as well as no template and no RT negative controls were included and at least three biological replicates were studied in each case. The sequence of the primers used are as follows: Rat PGC-1 α –F: 5'-gaatgcagcgtcttagc-3', -R: 5'-gct ttt gct gtt gac aaa tg-3' rat GAPDH–F: 5'-aga agg ctg ggg ctc acc-3' 200 nM, -R: 5'-agt tgg tgg tgc agg atg c-3' 100 nM; 18s rRNA–F: 5'-gtg gag cga ttt gtc tgg tt-3', -R: 5'-caa gct tat gac ccg cac tt-3'. The cycling programme was 10 min at 95°C; 40 cycles of 30 s at 95°C, 40 s at 60°C with detection of fluorescence and 30 s at 72°C; 1 cycle (for dissociation curve) of 1 min at 95°C and 30 s at 55°C with a ramp up to 30 s at 95°C (ramp rate: 0.2°C/s) with continuous detection of fluorescence on the 55°C–95°C ramp. The data were analyzed using the MxPro QPCR analysis software (Stratagene). Expression of the gene of interest was normalized to GAPDH, a commonly used

control, which is invariant against a second control [18s rRNA (32)].

Plasmids

TR-Luc and GFP-SMRT α full length was a gift from Martin Privalsky [UC Davis (17)]. For construction of GFP-SMRT^{1233–2472}, GFP-SMRT^{1523–2472}, GFP-SMRT^{1–590}, GFP-SMRT^{1–1854}, and GFP-SMRT^{1–1018}, GFP-SMRT α was digested with *Hind*III and *Eco*RI, *Hind*III and *Pml*I, *Sfi*I and *Xho*I, *Bsr*U36I and *Xho*I, and *Pml*I and *Xho*I, respectively, and then the ends were blunted using DNA Polymerase I Large (Klenow) Fragment (Promega) enzyme and religated. For the construction of GFP-SMRT ^{Δ 1018–1523} GFP-SMRT α was digested with *Pml*I to remove the nucleotides coding for the region 1018–1523 and religated. For the construction of GFP-SMRT^{1–1523} an *Mlu*I restriction site was inserted by directed mutagenesis and digested with *Mlu*I and *Xho*I blunt ended and religated. GFP-SMRT ^{Δ 1609–1697} and GFP-SMRT ^{Δ 1681–1694} was constructed by amplifying by PCR the whole GFP-SMRT α plasmid except the nucleotides coding for the region 1609–1697 and 1681–1694 by using the primers forward 5'-ata cgc gtg ggt atg gag gtg ggg tca aa-3' and reverse 5'-taa cgc gtg ccg ctg gcc caa gag gca tt-3' and forward 5'-ata cgc gtc atg tca gca cgc tgg gcc at-3' and reverse 5'-taa cgc gta att atg ccg ctg gcc caa gag-3', respectively, which contain an *Mlu*I restriction site (adding to the sequence two extra amino acids, Thr and Arg). The PCR product was digested with *Mlu*I and religated. To clone the repression domain 3 (RD3)-myc (SMRT^{1024–1526}) this region was amplified using the primers forward 5'-acg aat tca tgc cag tgc ctc ctg ccg aga aag ag-3' and 5'-cgc tct aga tca cag atc ttc ttc aga aat aag ttt ttg ttc tgg cag gtg act ggt gaa ggg-3', PCR product was cloned in *Xba*I/*Eco*RI sites of pEF1/V5-His A expression vector (Invitrogen). pTK-RL was from Promega. PGC-1 α -luc and PGC-1 α ^{ACRE}-luc were a gift from A. Fukamizu (University of Tsukuba (7)); GAL4-PGC-1 α , pcDNA-PGC-1 α , and pcDNA-PGC-1 α -3A were a gift from P. Puigserver (Dana Farber Cancer Institute); pcDNA-PGC-1 α -3D was from Addgene (8). PGC-1 α and PGC-1 α -3D was subcloned in the pEF/V5-His A vector (Invitrogen) by excising the cDNA from the pcDNA vector with *Eco*RI and *Age*I digestion and blunting it to clone it in the *Eco*RV site of the pEF/V5-His A vector.

Immunofluorescence

Immunofluorescence was performed as described (26). Pictures of GFP-SMRT construct-expressing neurons were taken on a CCD camera driven by Openlab software, and the subcellular distribution scored. Distribution was scored as nuclear if localization was exclusively nuclear, whereas significant observable GFP immunofluorescence in the cytoplasm counted as a cell that exhibited SMRT export. Anti-GFP antibody (Invitrogen) was used (1:600) and observed using biotinylated secondary antibody/cy3-conjugated streptavidin. Nuclei were counter-stained with DAPI. For each treatment, ~150–200 cells were analyzed within 3–5 independent experiments.

Transfections and gene expression analysis

Neurons were transfected using Lipofectamine 2000 (Promega) and stimulated 24–48 h after transfection. For gene

expression analysis cells were then incubated overnight or for 8 h and luciferase activity read out. Luciferase assays were performed using the Dual Glo assay kit (Promega) with Firefly luciferase-based reporter gene activity normalized to the Renilla control (pTK-RL plasmid) in all cases. Mean $\pm$ SEM of 3–6 experiments is shown. Where used, siRNA (PGC-1 α or Dharmacon's control nontargeting siRNA #2 siRNA) was at 100 nM. siRNA sequences used were as follows: (i) 5'-caa uga aug cag cgg ucu u-3'; (ii) 5'-gaa caa gac uau uga gcg a-3'.

Following the fate of transfected cells

This was performed essentially as described (43). Briefly, pictures of GFP-expressing neurons were taken using a Leica AF6000 LX imaging system, with a DFC350 FX digital camera. Neurons were then treated with 100 μ M H₂O₂ or 30 μ M NMDA and images of the same cells were taken 24 h after H₂O₂ exposure. Cell death was assessed by counting the number of surviving GFP-positive neurons pre- and post-exposure to H₂O₂. In the vast majority of cases, death was easily spotted as an absence of a healthy GFP-expressing cell where one once was. In place of the cell, there was in most cases (>90%) evidence of death in the form of fragmented neurites, fluorescent cell debris, and an apoptotic nucleus. This confirmed that the cells were genuinely dying as opposed to a more unlikely scenario such as peroxide-induced quenching of eGFP fluorescence in a sub-population of neurons. This is also underlined by the fact that death measured by this technique is blocked by caspase inhibitors (32). For each plasmid/condition, the fate of ~150–200 neurons was monitored over 3–5 independent experiments.

Results

PGC-1 α is strongly protective against oxidative and excitotoxic insults

To assess the extent of neuroprotection afforded by PGC-1 α in primary cortical neurons, we transfected neurons with a vector encoding PGC-1 α driven by a constitutively active promoter, plus an eGFP vector to identify transfected neurons. The fate of these neurons was monitored both before and after the application of an oxidative insult (100 μ M H₂O₂). Consistent with the known ability of PGC-1 α to boost antioxidant defenses in other systems, expression of PGC-1 α rendered cortical neurons essentially resistant to this oxidative insult (Fig. 1A, B). Further, this protective effect appeared to be cell autonomous: no significant resistance to oxidative insults was observed in untransfected neurons even when in proximity to the PGC-1 α -expressing neurons (Fig. 1C). We also investigated the effect of siRNA directed against PGC-1 α on neuronal viability. Validation of PGC-1 α -directed siRNA was hampered by the absence of a PGC-1 α antibody that detects endogenous neuronal PGC-1 α by immunohistochemistry at this developmental stage (in our hands), and the fact that siRNA transfection efficiency is too low to analyze knock-down of endogenous protein by Western blot. Instead, we overexpressed Flag-tagged PGC-1 α and analyzed the effectiveness of the siRNA in preventing PGC-1 α expression, finding one that worked particularly well (siRNA #2, Fig. 1D inset). We confirmed the efficacy of this siRNA by showing that it completely blocked the protective effect of PGC-1 α

FIG. 1. Expression of peroxisome proliferator-activated receptor- γ coactivator 1 α (PGC-1 α) protects neurons against neurotoxic insults. **(A)** Expression of PGC-1 α in cortical neurons protects against H₂O₂-induced neuronal death. The neurons were transfected with control (globin) or PGC-1 α vector, plus an enhanced green fluorescent protein (GFP) expression vector to monitor cell fate (see Materials and Methods). Twenty-four hours post-transfection neurons were treated where indicated with H₂O₂ (100 μ M) and cell fate monitored after a further 24 h. Scale bar = 30 μ m. **(B)** Quantification of data shown in A. Death indicated by loss of GFP-positive cells. Transfected neurons were identified after 24 h and their fate was monitored at 24 h. 100–160 neurons were studied per treatment across five independent experiments. * p < 0.05, Bonferonni two-tailed paired t -test in this and subsequent figures unless stated. Mean $\pm$ SEM shown here and throughout all figures. **(C)** Cell autonomous effect of PGC-1 α expression on H₂O₂-induced neuronal death. Survival/death of neurons within a 150 μ m radius of PGC-1 α -expressing neurons was analyzed by assessing nuclear morphology of DAPI-stained fixed cells. As can be seen in A, healthy neurons have large nuclei with diffuse DAPI staining. Apoptotic nuclei are characterized by pyknotic brightly stained clumps of condensed chromatin. **(D)** Knock-down of PGC-1 α makes cortical neurons more sensitive to H₂O₂-induced neuronal death. Survival/death of neurons transfected with a control siRNA or siRNA directed against PGC-1 α were treated as in A 48 h after transfection * p < 0.05 (n = 4). An example of a Western validating the siRNA efficacy is also shown. **(E)** Expression of PGC-1 α protects cortical neurons against N-methyl D-aspartate (NMDA)-induced cell death. Neurons were transfected as in A and treated with NMDA (30 μ M) for 1 h. After 24 h they were fixed and death assessed. * p < 0.05 (n = 5).

overexpression when cotransfected with the PGC-1 α expression vector (data not shown). This siRNA, when transfected into neurons, had the effect of increasing the amount of death observed after H₂O₂ exposure (Fig. 1D), indicating that endogenous PGC-1 α is a regulator of cortical antioxidant defenses, in agreement with previous studies on neuroblastoma cells and striatal neural progenitor cells (45).

PGC-1 α has also been reported to confer protection against excitotoxic insults such as kainate-induced seizure, oxygen-glucose deprivation, and mtHtt-induced death (6, 25, 31, 45). While excitotoxic insults undoubtedly have an oxidative component, other routes to neuronal death are also triggered that are not associated with oxidative stress (13). We therefore wanted to know whether PGC-1 α protected against an excitotoxic insult in our system as effectively as it did for oxidative insults. We exposed control- and PGC-1 α -

expressing cortical neurons to an excitotoxic dose of NMDA and once more saw near complete resistance to this insult (Fig. 1E).

SMRT specifically represses the antioxidant boosting effects of PGC-1 α

As a coactivator, PGC-1 α promotes the transactivating potential of many transcription factors, including nuclear receptors and MEF2s. These and other transcription factors associate with PGC-1 α -containing coactivator complexes when active but also are capable of mediating active transcriptional repression when associated with corepressor complexes in their inactive state. Taking the example of nuclear hormone receptors, their coactivator- and corepressor-associated forms exist in an equilibrium that is pushed in favor of the active

FIG. 2. Expression of silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) blocks specifically the protective effect of PGC-1 α on H₂O₂-mediated cell death but not the NMDA-mediated cell death. Cortical neurons were transfected with a eGFP-encoding vector plus the indicated vectors (encoding PGC-1 α and/or SMRT), with the control vector used wherever either vector was not transfected. Twenty-four hours after transfection, pictures were taken of transfected neurons before they were treated with 100 μ M H₂O₂ (A) or 30 μ M NMDA (B), and cell fate monitored after a further 24 h. * p < 0.05 (n = 5 for A and B). ns, not significant.

state by presence of cognate ligand but can also be influenced by the level of corepressors or coactivators available (41).

SMRT is a transcriptional corepressor that exerts its effects by binding target transcription factors and recruiting other repressor molecules such as HDACs. It shares several targets with PGC-1 α , including nuclear receptors and MEF2s, raising the possibility that SMRT could exert opposite effects to PGC-1 α with respect to vulnerability of neurons to oxidative and excitotoxic insults. We therefore investigated the effect of SMRT expression on vulnerability to these trauma. We found that expression of SMRT alone did not affect basal viability (data not shown), nor did it increase neuronal vulnerability to H₂O₂-induced oxidative death (Fig. 2A). However, SMRT completely blocked the protective antioxidant effects of PGC-1 α expression (Fig. 2A). We next looked at the effect of SMRT expression on the vulnerability of neurons to NMDA receptor (NMDAR)-dependent excitotoxic death. In this case, SMRT expression alone did not exacerbate cell death but neither did it antagonize the protective effect of PGC-1 α expression (Fig. 2B). Thus, SMRT antagonizes the antioxidant effects of PGC-1 α but not the antiexcitotoxic effects. This indicates that these two PGC-1 α -driven neuroprotective effects are mechanisti-

cally different, and that SMRT specifically antagonizes those PGC-1 α -mediated events that ultimately boost resistance to oxidative insults.

Synaptic NMDAR activity boosts PGC-1 α transcription in vitro and in vitro

Synaptic activity, acting in part by triggering synaptic NMDAR-dependent Ca²⁺ transients, is able to control the activity, expression, and subcellular localization of several broad specificity transcriptional coactivators and corepressors. We next investigated the influence of synaptic activity on PGC-1 α and SMRT function and its implications for the antagonistic effect of SMRT on PGC-1 α -dependent antioxidative effects.

Membrane depolarization, triggering Ca²⁺ entry, is known to upregulate the transcription of PGC-1 α (29), indicating that synaptic activity is likely to do the same. We used an established method of network disinhibition to enhance synaptic activity, by applying the gamma-aminobutyric acid A receptor antagonist BiC. This treatment results in synchronized bursts of action potentials that are associated with intracellular

FIG. 3. Synaptic activity induces PGC-1 α gene expression in a cyclic-AMP response element binding protein (CREB)-dependent manner. (A) Synaptic activity was induced in cortical cultures by bicuculline (BiC, 50 μ M) plus 4-amino pyridine (250 μ M; labeled BiC, here and through the study) for 24 h followed by RNA extraction and quantitative RT polymerase chain reaction analysis of PGC-1 α mRNA expression (normalized to GAPDH). A Western of PGC-1 α (Akt is used as loading control) is also shown. * p < 0.05 (n = 4). (B) *In vivo* N-methyl D-aspartate receptor blockade reduces PGC-1 α mRNA levels. P6 mice were subjected to intraperitoneal injection of saline (Con) or MK-801 (for 12 h) followed by RNA extraction and quantitative RT polymerase chain reaction analysis of PGC-1 α mRNA expression (normalized to GAPDH, * p < 0.05 [n = 4]). (C) The promoter of PGC-1 α is activated in a CREB-dependent manner by synaptic activity. A PGC-1 α -luc reporter of the wild-type promoter or with the CREB binding site mutated (PGC-1 α ^{ΔCREB}-luc) was transfected in cortical neurons, after 24 h the culture was stimulated with BiC for 24 h and luciferase activity was read (normalized to renilla here and in all luciferase assays; see Materials and Methods). * p < 0.05 (n = 3).

Ca^{2+} transients dependent on influx through NMDARs, as well as release from internal stores and some influx through voltage-gated channels (14). The K^+ channel antagonist 4-aminopyridine (4-AP) was coapplied with BiC to enhance burst frequency (14) (hereafter BiC/4-AP). BiC/4-AP treatment resulted in the upregulation of PGC-1 α mRNA and protein expression (Fig. 3A). *In vivo*, suppression of physiological NMDAR activity by treatment with MK-801 caused a downregulation of PGC-1 α expression (Fig. 3B), indicating that PGC-1 α is regulated by activity both *in vitro* and *in vivo*. PGC-1 α is a known target of the transcription factor cyclic-AMP response element binding protein (CREB) that is itself known to be strongly activated by synaptic NMDAR activity. Synaptic activity induced a luciferase based reporter of the PGC-1 α promoter that was impaired if the CRE site was mutated (Fig. 3C), strongly indicating that activity-dependent induction of PGC-1 α is *via* CREB.

Synaptic activity boosts PGC-1 α activity post-translationally via p38.

As well as being subject to transcriptional regulation, PGC-1 α has also been reported to be subject to post-translational control. Cytokine stimulation of muscle cells has been shown to induce PGC-1 α 's intrinsic activity *via* its p38-dependent phosphorylation (36) that prevents the binding of the repressor protein p160^{MBP} (8).

Since synaptic activity can trigger p38 activity (44) we considered the possibility that PGC-1 α could be subject to activity-dependent post-translational control. To study the post-translational regulation of PGC-1 α directly we tested the ability of PGC-1 α , tethered to the promoter by means of fusion to a GAL4 DNA binding domain, to confer activity-dependent inducibility on a luciferase-based reporter containing multiple GAL4 binding sites. Expression of GAL4-PGC-1 α resulted in an 11-fold activation of the reporter compared to expression of the GAL4 domain alone (Fig. 4A), consistent with a significant degree of basal activity. However, triggering synaptic activity with BiC/4-AP resulted in a further fivefold enhancement of PGC-1 α -dependent gene expression, indicating that PGC-1 α 's intrinsic activity is enhanced by neuronal activity (Fig. 4B). To investigate this further we looked at the role of p38 in this activation process. We found that pretreatment with the p38 inhibitor SB202580 strongly inhibited the potentiating effect of synaptic activity on GAL-PGC-1 α -mediated reporter activity (Fig. 4B).

PGC-1 α promotes the activation of nuclear receptors, including the TR (37, 38). TR-mediated gene expression is suppressed by SMRT, and so represents an example of one of several transcription factors that could integrate the opposing actions of PGC-1 α and SMRT. We recently found that synaptic activity can super-induce T3 hormone activation of the TR. This was associated with the activity-dependent nuclear export of SMRT and the dissociation of SMRT from TR promoter

FIG. 4. Synaptic activity enhances the transcriptional activity of PGC-1 α in a p38-dependent manner. (A) Neurons were transfected with an UAS^{GAL4}-luc reporter vector plus vectors encoding either GAL4 DNA binding domain alone or GAL4-PGC-1 α expression vector. Twenty-four hours post-transfection luciferase activity was measured. $*p < 0.05$ ($n = 4$). **(B)** Synaptic activity-mediated increase in PGC-1 α transcriptional activity *via* p38 signaling. Cortical neurons were transfected with an UAS^{GAL4}-luc reporter vector plus pTK-Renilla plus GAL4-PGC-1 α expression vector. Twenty-four hours post-transfection luciferase neurons were stimulated with BiC in the absence or presence of the p38 inhibitor SB202580 added at 5 μM 30 min before the stimulation, and after 8 h luciferase activity was measured. $*p < 0.05$ ($n = 4$). **(C)** Synaptic activity-dependent enhancement T3 hormone-responsiveness is p38 dependent. Neurons were transfected with an thyroid hormone receptor (TR)-luc reporter vector, plus pTK-Renilla. Twenty-four hours post-transfection, neurons were stimulated

with BiC in the absence or presence of T3 hormone (50 nM). Where used, the p38 inhibitor SB202580 was added at 5 μM 30 min before the stimulation. After 16 h stimulation, luciferase activity was measured. $*p < 0.05$ ($n = 4$). $\#p < 0.05$ compared to equivalent non-T3 treated condition. **(D)** Mutation of the three p38 phosphorylation sites on PGC-1 α abolish the synaptic activity-mediated enhancement of T3-responsiveness. Neurons were transfected with a TR-luc reporter vector plus PGC-1 α or PGC-1 α ^{3A} in which amino acids T262, S265, and T298 (sites phosphorylated by p38) have been mutated to Alanine. Twenty-four hours post-transfection neurons were stimulated (where indicated) with 50 nM T3 $\pm$ BiC for 24 h. $*p < 0.05$ ($n = 4$). $\#p < 0.05$ compared to equivalent non-BiC treated condition.

elements (28). Our observation that PGC-1 α can also be regulated by synaptic activity raised the possibility that activity-dependent activation of PGC-1 α *via* p38 may contribute to this process. We first assessed the role of p38 in the induction of T3-responsiveness by synaptic activity. In agreement with our previous study, synaptic activity did not induce TR reporter activity in the absence of hormone (Fig. 4C). However, in the presence of T3, coincident BiC/4-AP-induced synaptic activity potentiated the response (Fig. 4C). Moreover, inhibition of p38 reversed this potentiation (Fig. 4C). Note that the effect of p38 inhibition was restricted to the potentiating effect of synaptic activity: neither basal TR reporter activity nor activity induced by T3 alone was inhibited by p38 inhibition. This rules out a nonspecific effect of p38 inhibition on overall ability of the TR to promote transcription.

We wanted to know if PGC-1 α is a target of the p38 pathway in boosting TR-mediated gene expression. p38-dependent activation of PGC-1 α is mediated by phosphorylation on three different sites (36). Mutation of these residues to alanine abolishes p38-inducibility of PGC-1 α -mediated processes without reducing basal PGC-1 α activity. We investigated the effect of this mutant (PGC-1 α ^{3A}) on the activity-mediated, p38-dependent boosting of TR-mediated gene expression. Compared to expressing wild-type PGC-1 α , expression of PGC-1 α -3A had the effect of specifically inhibiting the potentiating effect of activity on TR-mediated gene expression (Fig. 4D). Basal T3-induced, TR-mediated gene expression (in the absence of synaptic stimulation) was not affected (Fig. 4D). We also confirmed that PGC-1 α ^{3A} has similar basal activity to wild-type PGC-1 α with regard to its ability to protect against H₂O₂-induced death (data not shown). The effect of PGC-1 α ^{3A} in specifically interfering with activity-mediated, p38-dependent boosting of TR-mediated gene expression suggests that phosphorylation of these sites may contribute to the p38-mediated effects observed.

SMRT's RD3 domain confers nuclear localization in neurons

We previously reported that synaptic activity promotes the nuclear export of SMRT and dissociation of SMRT from target transcription factors including the TR (28). Activity-dependent redistribution of SMRT to the cytoplasm is observed in the presence of the protein synthesis inhibitor cycloheximide (data not shown), confirming that the pre-existing SMRT is exported (rather than, *e.g.*, newly synthesized SMRT being retained in the cytoplasm). Thus, neuronal synaptic activity can inactivate SMRT as well as activate PGC-1 α . To investigate this nuclear export further we created deletion mutants of SMRT spanning its entire 2472 amino acids.

We first investigated the region(s) of SMRT that confer nuclear localization under normal conditions in neurons. A C-terminal portion of SMRT (SMRT^{1223–2472}) was nuclear-localized, but this was lost in the SMRT^{1523–2472} portion, implicating the 1223–1523 region (Fig. 5B, C). Consistent with this, an internal deletion of region 1018–1523 (SMRT^{Δ(1018–1523)}), which encompasses SMRT's RD3 domain, caused a reduction (but not complete loss) in nuclear localization (Fig. 5C). In contrast, deletion of a region spanning SMRT's RD4 domain (SMRT^{Δ(1523–1854)}) did not affect nuclear localization. Further, a portion of SMRT containing the RD3 region (SMRT^{1025–1523}) is nuclear when expressed (Fig. 5C), as

has been reported in HeLa cells (50). Thus, the RD3 domain is an important determinant of SMRT nuclear localization in neurons.

However, the fact that SMRT^{Δ(1018–1523)} retained some nuclear localization (Fig. 5C) is suggestive of further sequences conferring nuclear localization in the N-terminal 1018 amino acids. Indeed, the N-terminal portion of SMRT (SMRT^{1–1018}) was also strongly nuclear when expressed, although a smaller region of SMRT (SMRT^{1–590}) was not, appearing to be distributed evenly throughout the nucleoplasm (Fig. 5C). Collectively these data indicate that the RD3 region is important for conferring SMRT nuclear localization, but that the N-terminal region can also localize to the nucleus independent of this domain.

SMRT N- and C-terminal sequences can mediate activity-dependent nuclear export

Study of the BiC/4-AP-induced export (Fig. 5D, E) revealed that SMRT^{1–1854} undergoes export as effectively as full-length SMRT but that SMRT^{1–1523} is exported slightly (but significantly) less well, implicating the region between 1523 and 1854 in contributing to nuclear export (Fig. 5E). Deletion of a smaller piece of this region (SMRT^{Δ1609–1697}) also showed a similar significant reduction in activity-dependent export (Fig. 5F). Further examination of this region revealed a potential nuclear export site (NES) (20) with sequence LRLGLSPRESSLA, which was deleted (SMRT^{Δ1681–1694}), once again showing a small but significant reduction in activity-dependent export (Fig. 5F).

Surprisingly, however, further C-terminal deletion beyond position 1523 (creating SMRT^{1–1018}) restored activity-dependent export to normal levels (Fig. 5E), suggesting that the 1018–1523 region of SMRT (containing the RD3 domain) acts as a partial break on nuclear export. This portion of SMRT (SMRT^{1025–1523}) does not undergo export in response to synaptic activity, remaining in the nucleus (Fig. 5G, H). Since both N-terminal SMRT^{1–1018} and C-terminal SMRT^{1233–2507} undergo normal activity-dependent export (Fig. 5E), we conclude that no single domain is likely to be critical for this process, although the putative NES region may play a partially nonredundant role.

Synaptic activity renders SMRT unable to suppress PGC-1 α -mediated antioxidative effects

We observed that coexpression of SMRT resulted in the antioxidant effects of PGC-1 α expression being inhibited (Fig. 2A). However, our findings that synaptic activity both induces the activity of PGC-1 α as well as triggering nuclear export of SMRT (Figs. 3–5) suggests that the capacity of SMRT to antagonize PGC-1 α effects will be reduced. We found that in BiC/4-AP-stimulated neurons, death induced by 100 μ M H₂O₂ was lower than in inactive neurons (compare Figs. 6A and 2A), which is in agreement with our recent observations that synaptic activity can boost intrinsic antioxidant defenses (13, 32). Nevertheless, expression of PGC-1 α in active neurons resulted in further protection from H₂O₂-induced death (Fig. 6A).

Importantly, PGC-1 α -mediated protection against oxidative insults was still observed in SMRT-expressing neurons (Fig. 6A). BiC/4-AP-induced synaptic activity rendered the antagonizing effect of SMRT ineffective. This is consistent with the effect of synaptic activity in enhancing PGC-1 α

FIG. 5. Several domains mediate the nuclear localization and activity-dependent nuclear export of SMRT. (A) Schematic illustrating the SMRT constructs generated and used in this figure. (B) Examples of the cellular localization of three different SMRT constructs. Arrowheads indicate transfected cells here and throughout the figure. (C) Several domains of SMRT confer nuclear localization. Neurons were transfected with the indicated SMRT constructs. Forty-eight hours after transfection the cellular localization of SMRT in >150 transfected neurons per construct was analyzed. $*p < 0.05$ ($n = 4-6$). (D) Synaptic activity induces nuclear export of SMRT. Example of the cellular localization of SMRT in neurons transfected with GFP-SMRT and stimulated for 8 h with BiC or left unstimulated. (E) Several domains mediate the nuclear export of SMRT by synaptic activity. The indicated SMRT constructs were transfected into neurons. Forty-eight hours after transfection the neurons were stimulated with BiC for 8 h and the cellular localization of SMRT was analyzed. $*p < 0.05$ ($n = 5-6$). (F) Analysis of activity-dependent export of SMRT lacking a region containing a putative NES. $*p < 0.05$ ($n = 4$). (G) Analysis of the (lack of) activity-dependent export in a region of SMRT corresponding to its repression domain 3 domain. $*p < 0.05$ ($n = 3$). (H) Example pictures from G. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars).

FIG. 6. SMRT nuclear export or constitutively active PGC-1 α prevent SMRT-mediated blockade of PGC-1 α mediated protection to H_2O_2 mediated cell death. (A) Cortical neurons were transfected with the indicated vectors and after 24 h were stimulated with BiC for further 24 h. After this time the neurons were then treated with H_2O_2 (100 μM) for a further 24 h, after which cell death was assessed. $*p < 0.05$ ($n = 5$). (B) Neurons expressing the indicated constructs were treated with H_2O_2 (100 μM) for 24 h after which cell death was assessed. In the PGC-1 α^{3D} vector the amino acids T262, S265 and T298 have been mutated to Aspartic acid to mimic phosphorylated residues. $*p < 0.05$ ($n = 4$).

activity and suppressing SMRT activity. As to which of these is most important, it is possible that both contribute. Unfortunately, because the activity-dependent export of SMRT is mediated by multiple domains it was not possible to create a nonexportable mutant of SMRT that could be tested for its ability to antagonize PGC-1 α -mediated effects in synaptically active neurons. As such, the importance of SMRT export can be predicted but is difficult to test experimentally.

To test whether PGC-1 α phosphorylation could counteract the suppressive effects of SMRT, we expressed a mutant form of PGC-1 α (PGC-1 α^{3D}) in which the three p38 phosphorylation sites have been mutated from serine/threonine to aspartate to mimic the p38-phosphorylated form of PGC-1 α (8). The effect of this mutation is to render PGC-1 α resistant to p160^{MBP}-mediated repression and thus enhance its basal activity (8). We found that expression of PGC-1 α^{3D} in neurons offered protection even when coexpressed with SMRT (Fig. 6B). The fact that SMRT could not completely suppress the effects of PGC-1 α^{3D} indicates that phosphorylation on these residues may be a contributing factor in regulating the antagonistic balance between SMRT and PGC-1 α with regard to controlling antioxidant defenses.

Discussion

We have shown here that the transcriptional coactivator PGC-1 α is positively regulated by neuronal activity *in vitro* and *in vivo* at the transcriptional level and at the post-translational level *in vitro*. We have also demonstrated that SMRT is able to antagonize the antioxidative, but not antiexcitotoxic effects of PGC-1 α . However, this antagonism is itself controlled/repressed by neuronal activity, potentially through a combination of the aforementioned enhancement of PGC-1 α activity, plus activity-dependent SMRT export.

PGC-1 α directs neuroprotective gene expression and its under-expression may contribute to neurodegenerative diseases

As a transcriptional coactivator, PGC-1 α controls the activity of many transcription factors and acts as a master regulator of several important physiological processes in neurons. PGC-1 α -deficient mice exhibit lowered expression of certain antioxidant genes in the brain, including Sod1, Sod2, and catalase (45). Further, they show increased loss of dopaminergic neurons in response to treatment with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which is metabolized to the mitochondrial toxin MPP⁺ in dopaminergic neurons). PGC-1 α -deficient mice also show heightened levels of hippocampal neuronal loss in a kainate seizure model of excitotoxic cell death (45) and suffer from spontaneous striatal lesions (22). Conversely, overexpression of PGC-1 α in neuroblastoma cells and also striatal progenitor cells protects against oxidative insults (45). PGC-1 α also promotes protection in models of ischemia (5, 25). Overexpression of PGC-1 α boosts mitochondrial density in cortical neurons, leading to increased ATP levels (47). Thus, as a regulator of mitochondrial function and antioxidant defenses, PGC-1 α is neuroprotective against a variety of insults.

It is possible that different (potentially overlapping) subsets of PGC-1 α regulated genes are responsible for protection against different types of insult. For example, protection

against a purely oxidative insult may rely heavily on the upregulation of antioxidant genes, whereas PGC-1 α -mediated resistance to excitotoxic insults may rely more on enhanced mitochondrial function and energy production. Indeed, the fact that SMRT can antagonize the antioxidative effects of PGC-1 α expression but not the antiexcitotoxic effects indicates that different genes may be responsible for these two types of neuroprotection.

Not only is PGC-1 α neuroprotective against oxidative and excitotoxic insults, but there is evidence that perturbation in PGC-1 α expression is a contributor to neurodegenerative disease, particularly HD. mtHtt interferes with CREB-dependent PGC-1 α expression, leading to mitochondrial dysfunction and metabolic defects (6, 49). PGC-1 α expression is lower in the striata of human HD patients, but not in the cerebellum or hippocampus, consistent with the brain region-specific effects of HD. As a further exacerbating factor, the striatum appears to be particularly vulnerable to loss of PGC-1 α expression above other brain regions (22). Overexpression of PGC-1 α protects both cortical and striatal neurons from mtHtt- and 3-NPA-induced cell death, whereas lentiviral transduction of PGC-1 α reduces striatal loss in a mouse model of the disease (6, 31, 47, 49). As well as being implicated in HD, a recent study hints at involvement in Alzheimer's disease (39) where PGC-1 α is reported to promote nonamyloidogenic Amyloid Precursor Protein processing. Further, PGC-1 α expression is lowered in human Alzheimer's disease patients as a function of dementia (39).

Dynamic control of PGC-1 α by neuronal activity

Expression of PGC-1 α in the brain is controlled by CREB (6, 31, 45) and boosted by synaptic NMDAR activity [this study and ref. (31)]. In contrast, activation of extrasynaptic NMDAR activity, which inhibits CREB activity (16) can suppress PGC-1 α expression in mtHtt-expressing neurons (31). The activity-dependent nature of the PGC-1 α gene suggests that PGC-1 α levels will mirror the activity history of the neuron and could represent a way by which the elevated metabolic and antioxidative demands placed on a neuron by high levels of electrical activity could be met. Moreover, our study indicates that PGC-1 α activity can be regulated by post-transcriptional mechanisms. Studies in myoblasts revealed that PGC-1 α contains a negative regulatory domain that recruits p160^{MBP}, resulting in lowered transactivation function (8). This association is disrupted by p38-mediated phosphorylation (8) representing a potential point of rapid post-translational control. We have shown here that p38 activity also boosts PGC-1 α activity in neurons and that a mutant nonphosphorylatable form of PGC-1 α inhibits p38-dependent enhancement of gene expression mediated by the TR, a nuclear receptor coactivated PGC-1 α . Moreover, the antioxidative effects of a phospho-mimetic mutant of PGC-1 α is resistant to suppression by SMRT, consistent with its higher transactivating potential (although an alternative explanation is that phosphorylation renders PGC-1 α refractory to SMRT repression). As discussed below, the physiological effects of PGC-1 α are also subject to indirect activity-dependent regulation *via* the nuclear export of the corepressor SMRT.

However, that p38-mediated phosphorylation of overexpressed PGC-1 α is not essential for protection by insults in the absence of SMRT coexpression. Overexpression of a mutant

nonphosphorylatable form of PGC-1 α confers resistance to both oxidative and excitotoxic insults (data not shown). Thus, any requirement for PGC-1 α phosphorylation may be in cases where SMRT expression is significant, or PGC-1 α levels are low.

Antagonism of PGC-1 α 's antioxidative effects by SMRT is inhibited by synaptic activity

It remains unclear exactly which transcription factors are responsible for PGC-1 α -mediated protection against oxidative insults, and it is likely that several are involved in coordinating a general elevation in ROS-metabolizing capacity. The fact that SMRT is able to antagonize the antioxidative effects of PGC-1 α suggests that key transcription factor mediators include those that are targets for both these coregulators. Such factors include (but are not restricted to) PPAR γ , ER, TR, RAR, and MEF2s (19, 35, 46, 50). All the aforementioned transcription factors have been reported to promote neuroprotective gene expression and/or resistance to oxidative insults (3, 9, 30, 34, 40).

One can envisage a scenario whereby the balance of PGC-1 α coactivator *versus* SMRT corepressor activity influences the activity of one or more of these factors, which in turn controls the ROS metabolizing capacity of the neuron. As mentioned above, the fact that SMRT cannot antagonize the ability of PGC-1 α to protect against an excitotoxic insult raises the possibility that a different subset of PGC-1 α -coactivated transcription factors is involved in protection against excitotoxic insults, than those involved in mediating the antioxidative effects of PGC-1 α (perhaps one or more key factors mediating the antiexcitotoxic effects are not a target for SMRT).

The finding that neuronal activity renders SMRT unable to antagonize the antioxidative effects of PGC-1 α could conceivably be due to either activity-dependent SMRT export or activity-dependent PGC-1 α activation. The fact that the phospho-mimetic PGC-1 α ^{3D} is refractory to SMRT-repression suggests that phosphorylation is sufficient in the context of overexpression at least. Although this may be sufficient in cases of strong activity or high PGC-1 α expression, SMRT export may also contribute in cases of modest levels of activity or low PGC-1 α expression. Neuronal activity, acting partly *via* nuclear Ca²⁺-dependent CaM kinase IV signaling, causes SMRT export, which is associated with disruption of SMRT interaction with its target transcription factors such as TR and RAR, and sensitization of these factors to activation by their cognate hormone (28). Blockade of nuclear Ca²⁺ signaling inhibits activity-dependent enhancement of neuronal responsiveness to TR and RAR activation by their cognate hormone (28). However, although nuclear Ca²⁺ signaling, causing SMRT export, can be important in activity-dependent potentiation of hormone-responsiveness, activation of PGC-1 α by p38 may also contribute, as outlined above.

Analysis of the regions of SMRT responsible for nuclear localization and activity-dependent nuclear export in this study have revealed that multiple domains are likely to be responsible in both cases. Nuclear localization of SMRT is disrupted in a mutant lacking the RD3 domain, which is the region of SMRT that interacts with Class IIa HDACs, which include HDAC4 and 5 (19). It is not currently clear whether this region contains a bone fide nuclear localization signal

(NLS) or whether SMRT is localized to the nucleus through association with nuclear factors such as Class IIa HDACs. Of note, class IIa HDACs also undergo activity-dependent export that occurs in advance of SMRT export (28) and so while SMRT is clearly not being dragged out of the nucleus by class IIa HDACs, their export may leave SMRT more sensitive to export (28). Analysis of the effect of nonexportable mutants of HDAC4 and HDAC5 on SMRT export (underway in the laboratory) will elucidate the interdependency of SMRT and Class IIa HDAC export by synaptic activity. The direct investigation of activity-dependent redistribution of multiple deletion and truncation mutants of SMRT in this study indicates that more than one domain must be responsible, since nonoverlapping N- and C-terminal regions of SMRT exhibit activity-dependent export (Fig. 5). Once again, we cannot currently distinguish between autonomous export and "piggy back export" *via* these domains, or through association with other factors, particularly given the many factors with which SMRT interacts.

Concluding Remarks

It is clear that the influence of activity-dependent Ca²⁺ signaling extends beyond the direct regulation of Ca²⁺-responsive transcription factors. By influencing the function of broad specificity coactivators and corepressors, activity-dependent signals have the capacity to influence broad programs of gene expression, including genes controlled by transcription factors that are not classically Ca²⁺-responsive. In demonstrating that neuronal activity can regulate the ability of PGC-1 α to protect neurons against oxidative insults, we have increased our understanding of how endogenous signals control the product of this important disease-associated gene.

Acknowledgments

The authors thank Martin Privalsky, Bruce Spiegelman, Marc Montminy, Pere Puigserver, and Akiyoshi Fukamizu for plasmids. The authors thank Chrysanthi Ikonomidou for samples taken from MK-801-treated mice. This work was funded by the Biotechnology and Biological Sciences Research Council, the Wellcome Trust, The Royal Society (to G.E.H.) the Medical Research Council, the EMBO Young Investigator Programme (to G.E.H.), Canadian Institute of Health Research (to K.F.S.B.), and The European Network of Neuroscience Institutes.

Author Disclosure Statement

No competing financial interests exist.

References

1. Bading H, Ginty DD, and Greenberg ME. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. *Science* 260: 181–186, 1993.
2. Bading H and Greenberg ME. Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. *Science* 253: 912–914, 1991.
3. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, and Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. *Biochem Soc Trans* 34: 1341–1346, 2006.

4. Chawla S, Vanhoutte P, Arnold FJ, Huang CL, and Bading H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. *J Neurochem* 85: 151–159, 2003.
5. Chen SD, Lin TK, Yang DI, Lee SY, Shaw FZ, Liou CW, and Chuang YC. Protective effects of peroxisome proliferator-activated receptors gamma coactivator-1alpha against neuronal cell death in the hippocampal CA1 subfield after transient global ischemia. *J Neurosci Res* 88: 605–613, 2010.
6. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, and Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. *Cell* 127: 59–69, 2006.
7. Daitoku H, Yamagata K, Matsuzaki H, Hatta M, and Fukamizu A. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. *Diabetes* 52: 642–649, 2003.
8. Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, Jaeger S, Erdjument-Bromage H, Tempst P, and Spiegelman BM. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. *Genes Dev* 18: 278–289, 2004.
9. Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, and Mao Z. Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. *Neuron* 38: 33–46, 2003.
10. Greer PL and Greenberg ME. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. *Neuron* 59: 846–860, 2008.
11. Handschin C. The biology of PGC-1alpha and its therapeutic potential. *Trends Pharmacol Sci* 30: 322–329, 2009.
12. Hardingham GE. Pro-survival signalling from the NMDA receptor. *Biochem Soc Trans* 34: 936–938, 2006.
13. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. *Biochem Soc Trans* 37: 1147–1160, 2009.
14. Hardingham GE, Arnold FJ, and Bading H. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. *Nat Neurosci* 4: 261–267, 2001.
15. Hardingham GE, Chawla S, Cruzalegui FH, and Bading H. Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. *Neuron* 22: 789–798, 1999.
16. Hardingham GE, Fukunaga Y, and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat Neurosci* 5: 405–414, 2002.
17. Hong SH and Privalsky ML. The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. *Mol Cell Biol* 20: 6612–6625, 2000.
18. Hu X and Lazar MA. Transcriptional repression by nuclear hormone receptors. *Trends Endocrinol Metab* 11: 6–10, 2000.
19. Jepsen K and Rosenfeld MG. Biological roles and mechanistic actions of co-repressor complexes. *J Cell Sci* 115: 689–698, 2002.
20. la Cour T, Kierner L, Molgaard A, Gupta R, Skriver K, and Brunak S. Analysis and prediction of leucine-rich nuclear export signals. *Protein Eng Des Sel* 17: 527–536, 2004.
21. Leveille F, Papadia S, Fricker M, Bell KF, Soriano FX, Martel MA, Puddifoot C, Habel M, Wyllie DJ, Ikonomidou C, Tolkovsky AM, and Hardingham GE. Suppression of the intrinsic apoptosis pathway by synaptic activity. *J Neurosci* 30: 2623–2635, 2010.
22. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jager S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, and Spiegelman BM. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. *Cell* 119: 121–135, 2004.
23. Lin JD. Minireview: the PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism. *Mol Endocrinol* 23: 2–10, 2009.
24. Loebrich S and Nedivi E. The function of activity-regulated genes in the nervous system. *Physiol Rev* 89: 1079–1103, 2009.
25. Luo Y, Zhu W, Jia J, Zhang C, and Xu Y. NMDA receptor dependent PGC-1alpha up-regulation protects the cortical neuron against oxygen-glucose deprivation/reperfusion injury. *J Mol Neurosci* 39: 262–268, 2009.
26. Martel M, Wyllie DJ, and Hardingham GE. In developing hippocampal neurons, NR2B-containing NMDA receptors can mediate signalling to neuronal survival and synaptic potentiation, as well as neuronal death. *Neuroscience* 158: 334–343, 2009.
27. McGill JK and Beal MF. PGC-1alpha, a new therapeutic target in Huntington's disease? *Cell* 127: 465–468, 2006.
28. McKenzie GJ, Stephenson P, Ward G, Papadia S, Bading H, Chawla S, Privalsky M, and Hardingham GE. Nuclear Ca²⁺ and CaM kinase IV specify hormonal- and Notch-responsiveness. *J Neurochem* 93: 171–185, 2005.
29. Meng H, Liang HL, and Wong-Riley M. Quantitative immuno-electron microscopic analysis of depolarization-induced expression of PGC-1alpha in cultured rat visual cortical neurons. *Brain Res* 1175: 10–16, 2007.
30. Mey J. New therapeutic target for CNS injury? The role of retinoic acid signaling after nerve lesions. *J Neurobiol* 66: 757–779, 2006.
31. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, and Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. *Nat Med* 15: 1407–1413, 2009.
32. Papadia S, Soriano FX, Leveille F, Martel MA, Dakin KA, Hansen HH, Kaindl A, Siflinger M, Fowler J, Stefovskaya V, McKenzie G, Craigon M, Corriveau R, Ghazal P, Horsburgh K, Yankner BA, Wyllie DJ, Ikonomidou C, and Hardingham GE. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. *Nat Neurosci* 11: 476–487, 2008.
33. Papadia S, Stevenson P, Hardingham NR, Bading H, and Hardingham GE. Nuclear Ca²⁺ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. *J Neurosci* 25: 4279–4287, 2005.
34. Peri A and Serio M. Neuroprotective effects of the Alzheimer's disease-related gene seladin-1. *J Mol Endocrinol* 41: 251–261, 2008.
35. Perissi V, Jepsen K, Glass CK, and Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. *Nat Rev Genet* 11: 109–123, 2010.
36. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, and Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. *Mol Cell* 8: 971–982, 2001.
37. Puigserver P and Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha):

- transcriptional coactivator and metabolic regulator. *Endocr Rev* 24: 78–90, 2003.
38. Puigserver P, Wu Z, Park CW, Graves R, Wright M, and Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* 92: 829–839, 1998.
 39. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, and Pasinetti GM. PGC-1 α expression decreases in the Alzheimer disease brain as a function of dementia. *Arch Neurol* 66: 352–361, 2009.
 40. Simpkins JW, Yi KD, and Yang SH. Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens. *Front Neuroendocrinol* 30: 93–105, 2009.
 41. Sohn YC, Kim SW, Lee S, Kong YY, Na DS, Lee SK, and Lee JW. Dynamic inhibition of nuclear receptor activation by corepressor binding. *Mol Endocrinol* 17: 366–372, 2003.
 42. Soriano FX and Hardingham GE. Compartmentalized NMDA receptor signalling to survival and death. *J Physiol* 584: 381–387, 2007.
 43. Soriano FX, Leveille F, Papadia S, Higgins LG, Varley J, Baxter P, Hayes JD, and Hardingham GE. Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. *J Neurochem* 107: 533–543, 2008.
 44. Soriano FX, Martel MA, Papadia S, Vaslin A, Baxter P, Rickman C, Forder J, Tymianski M, Duncan R, Aarts M, Clarke P, Wyllie DJ, and Hardingham GE. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. *J Neurosci* 28: 10696–10710, 2008.
 45. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, and Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. *Cell* 127: 397–408, 2006.
 46. Varlakhanova N, Snyder C, Jose S, Hahm JB, and Privalsky ML. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. *Mol Cell Biol* 30: 1434–1445, 2010.
 47. Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, and Kaasik A. PGC-1 α and PGC-1 β regulate mitochondrial density in neurons. *J Biol Chem* 284: 21379–21385, 2009.
 48. West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser JM, Shaywitz AJ, Takasu MA, Tao X, and Greenberg ME. Calcium regulation of neuronal gene expression. *Proc Natl Acad Sci U S A* 98: 11024–11031, 2001.
 49. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, and La Spada AR. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1 α in Huntington's disease neurodegeneration. *Cell Metab* 4: 349–362, 2006.
 50. Wu X, Li H, Park EJ, and Chen JD. SMRTE inhibits MEF2C transcriptional activation by targeting HDAC4 and 5 to nuclear domains. *J Biol Chem* 276: 24177–24185, 2001.

Address correspondence to:
 Prof. Giles E. Hardingham
 Centre for Integrative Physiology
 University of Edinburgh
 Edinburgh EH8 9XD
 United Kingdom

E-mail: giles.hardingham@ed.ac.uk

Date of first submission to ARS Central, September 3, 2010;
 date of acceptance, September 19, 2010.

Abbreviations Used

4-AP	= 4-aminopyridine
BiC	= bicuculline
CREB	= cyclic-AMP response element binding protein
eGFP	= enhanced green fluorescent protein
ER	= estrogen receptor
HD	= Huntington's disease
HDAC	= histone deacetylase
MEF2	= myocyte enhancer factor 2
mtHtt	= mutant Huntingtin
NMDAR	= N-methyl D-aspartate receptor
PGC-1 α	= peroxisome proliferator-activated receptor- γ coactivator 1 α
PPAR γ	= peroxisome proliferator-activated receptor- α
qPCR	= quantitative polymerase chain reaction
RAR	= retinoic acid receptor
RD	= repression domain
SMRT	= silencing mediator of retinoic acid and thyroid hormone receptors
TR	= thyroid hormone receptor